top of page

Investment Opportunity

Corporate Profile

Healiva® is a patient-centric Biotech company, delivers precision medicine to improve people’s quality of life. We are the first Biotech offering multiple end-to-end, intuitive wound care solutions that could be personalized whilst remaining affordable. Wound healing is the intricate process and the biological complexity of this sequence of events means that despite the majority of superficial wounds heal without issue, this process can go awry resulting in a non-healing, chronic wound. These can take months, even years to heal with current treatment approaches. Non-healing, chronic wounds represent a significant burden to both patients’ quality of life and to healthcare systems. About 60% of chronic wounds remain unhealed. In the EU, between 1.5 and 2m people are living with chronic wounds, with Switzerland alone being home to over 300,000. Starkly, this consequence is also on the rise, with limb amputation increasing by nearly 20% between 2014-2017 when compared to 2010-2013. Healiva®’s pipeline products are poised to reduce the cost to heal a wound by addressing these factors directly, providing solutions that are not only highly effective, but also easy-to-use, cost-effective, and accessible.

Customer Focus

Our customer base is multifaceted, encompassing hospitals, medical practitioners, insurance providers, and the patients themselves. Healiva’s pipeline products will target key pain-points for our customers and specialist medical expertise to allow patients to re-establish their normal work/life routines.

Market size and growth

The wound care market stands at €21.7B in 2022 according to PitchBook Data, growing at a CAGR of 8% to 2026. The Enzymatic debridement segment alone (healiva 003) accounts for €0.58b annually. Nearly 15% of Medicare beneficiaries (8.2m) have more than one type of wound, or a wound-related infection, accounting for annual direct spending of >$28.1B in the USA.

Transaction overview

Healiva® announced on June 1st, 2022 acquisition of two wound-healing cell therapy Assets From Smith+Nephew. With this acquisition, Healiva adds two close-to-market innovative technologies to Healiva’s® growing portfolio of end-to-end care for chronic wounds. 

Healiva® announced on November 21st, 2022 acquisition of Critical Cell Therapy Manufacturing Assets From B. Braun. The acquisition will accelerate the launch of Healiva’s personalized skin regeneration therapy, EpiDex®.

For further information on investment opportunity in Healiva do not hesitate to get in touch with us by clicking here Healiva® Investment opportunity or by clicking the below

bottom of page